TBI patients' brains were estimated to be older than their chronological age. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Delayed discharge is associated with higher hospital costs and complication rates especially nosocomial infections. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
After carefully reviewing the literature, the group concluded that there were insufficient data to make evidence-based recommendations. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome, which arises in individuals carrying an extra copy of chromosome 21, is associated with a greatly increased risk of early-onset Alzheimer disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
52/100
Dementia affects about 5% of the elderly population over age 65 years and has an unexplained predominance in women and a low rate in some cultures. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Diabetes mellitus is associated with an increase in the risk of dementia and the proportion of patients who convert from mild cognitive impairment (MCI) to dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The gender-specific results for obesity, but not for diabetes, suggests that the underlying mechanisms linking them to cognition may be different. 2 key findings →
Participants: 551 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The incidence of CA-AKI among all hospital admissions was 4.3% compared with an incidence of 2.1% of HA-AKI, giving an overall AKI incidence of 6.4%. 2 key findings →
Participants: 15,976 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Individuals with DS have a substantially increased risk of mortality due to specific causes and may have an elevated risk of other incident cancers in addition to leukemia. 4 key findings →
Participants: 22 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
On long-term follow-up (median 15 years; minimum-maximum, 0-20), participants developed cardiometabolic disease (hypertension [1255 events]; diabetes [381 events]), chronic kidney disease (529 events), dementia (235 events), cardiovascular disease (684 events) a 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cerebral microbleeds (CMBs) are MRI markers attributed to the most common cerebral angiopathies in the elderly and in patients with dementia: hypertensive and cerebral amyloid angiopathy. 4 key findings →
Participants: 85 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There is a wide interest in biomarkers that capture the burden of detrimental factors as these accumulate with the passage of time, i.e., increasing age. 4 key findings →
Participants: 1,961 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Herpes simplex virus 1 (HSV1) is a neuroinvasive virus capable of entering the brain which makes it a candidate pathogen for increasing risk of dementia. 4 key findings →
Participants: 244 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Visual impairment and interventions to preserve vision may impact dementia risk. 4 key findings →
Participants: 300,823 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The authors observed that “Our findings showed that nurses provided chronic disease management that was acceptable, feasible and sustainable.” 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that significantly increases the risk of cardiovascular disease, which is the leading cause of morbidity and mortality among diabetic patients. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of the 799 participants (mean [SD] age, 46.2 [11.6] years; 424 women [53.1%]) randomized, 641 completed the 12-month follow-up and were included in the intention-to-treat analysis: 341 (n = 4 mosques) in the intervention group and 300 (n = 4 mosques) in the control group. 5 key findings →
Participants: 799 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Hearing aid use was associated with a modestly lower risk of probable dementia overall (Hazard Ratios, HR, 0.91), but the association was confined to participants reporting improvements in hearing (HR 0.86), with no apparent benefit among those reporting poor improvement in hearing (HR 0.98). 2 key findings →
Design: longitudinal study Participants: 61,089 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
52/100
Cardiovascular disease (CVD) is the leading cause of mortality globally, with over 20 million deaths each year. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundIndividuals with type 2 diabetes have an increased risk of developing both vascular and Alzheimer's dementia. 4 key findings →
Design: cohort study Participants: 128 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 36 251 participants were included with a median follow-up time of 13.9 years. 5 key findings →
Participants: 251 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Over a follow-up period of 6.2 years, 513 participants were diagnosed with dementia. 5 key findings →
Design: cohort study Participants: 513 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study aims to assess the burden of young-onset dementia worldwide, regionally, and nationally during 1990-2021. 5 key findings →
Participants: 100,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
52/100
Adjudicated AKI, which was largely mild and reversible, was independently associated with increased risk of probable dementia and the composite of probable dementia and MCI in older adults at high cardiovascular risk. 5 key findings →
Design: cohort study Participants: 270 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We conducted a retrospective cohort study using the National Health Insurance Database in South Korea. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 3,290 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Central auditory dysfunction as a harbinger of Alzheimer dementia
- Ambient air pollution and clinical dementia: systematic review and meta-analysis
- Effect of Area-Level Socioeconomic Deprivation on Risk of Cognitive Dysfunction in Older Adults
- Healthy centenarians do not exist, but autonomous centenarians do: a population-based study of morbidity among Danish centenarians
- Beyond Usual Pace: Quick Walking Speed and Brain Health Outcomes in the Framingham Heart Study
- Characterization of Hispanic, African American, and non‐Hispanic White individuals living in disadvantage neighborhoods: the HABS‐HD Study
- Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology
- Declining Incident Dementia Rates Across Four Population-Based Birth Cohorts
- Clinical uses of melatonin: evaluation of human trials
- Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →